Promoted Content Promoted Content


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): 17α-ethynyl-androst-5-ene-3,7,17-triol

            Therapeutic Area: Endocrinology Product Name: NE3107

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 29, 2021


            NE3107, a new drug candidate in development for Alzheimer’s and Parkinson’s Diseases and other conditions, is an ERK inhibitor that selectively inhibits neuroinflammation and insulin resistance.